Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of switching virologically suppressed adults with HIV-1 from BIC/FTC/TAF to once-weekly islatravir + MK-8507
2020-003071-18Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of islatravir and ulonivirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoint: Percentage of participants with HIV-1 RNA greater than or equal to 50 copies/mL. Started Sep 2020; status: active.
02
Drugs
islatravirulonivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2020-003071-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003071-18.